Immutep Ltd ( (AU:IMM) ) has issued an update.
Immutep Limited announced its participation in several upcoming investor conferences, including the Jones Healthcare and Technology Innovation Conference, the Citizens Life Sciences Conference, and the Jefferies Global Healthcare Conference. This engagement reflects Immutep’s proactive approach to investor relations and its efforts to showcase its advancements in immunotherapy, potentially enhancing its industry position and stakeholder engagement.
More about Immutep Ltd
Immutep Limited is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a leader in the field of Lymphocyte Activation Gene-3 (LAG-3) therapeutics, aiming to harness LAG-3’s potential to modulate immune responses. Immutep is committed to delivering innovative treatments to patients and maximizing shareholder value.
YTD Price Performance: -9.09%
Average Trading Volume: 5,000
Technical Sentiment Signal: Strong Buy
Current Market Cap: $254.4M
See more insights into IMM stock on TipRanks’ Stock Analysis page.